FENC FENNEC PHARMACEUTICALS INC.

8-K Current Report

Filed: March 4, 2026

Health Care

Biological Products, (No Diagnostic Substances)

FENNEC PHARMACEUTICALS INC. (FENC) 8-K current report filed with SEC EDGAR on March 4, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 8.01: Other Events

AI Filing Analysis
8-K

Item 8.01 · Other Events

• Tampa General Hospital Cancer Institute initiating real-world study of PEDMARK® (sodium thiosulfate injection) in ototoxicity prevention
• Study expands PEDMARK® target population beyond current approved use — into adolescent, young adult, and adult cancer patients receiving cisplatin

+2 more insights

Other FENNEC PHARMACEUTICALS INC. 8-K Filings

8-K Mar 16, 2026

Get deeper insights on FENNEC PHARMACEUTICALS INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.